sameAs
Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infectionsZika Virus: Anatomy of a Global Health CrisisAbstral (Fentanyl Sublingual Tablets for Breakthrough Cancer Pain)American society of clinical oncology, 2010 annual meeting and rose bengal: from a wool dye to a cancer therapyGuanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity DisorderPharmaceutical approval updateRole of Tapentadol Immediate Release (Nucynta) in the Management Of Moderate-to-Severe PainUsing Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in YouthsAmerican society of hypertension and american urological associationH.p. Acthar gel and cosyntropin review: clinical and financial implicationsSpontaneous bacterial peritonitis: a review of treatment optionsMedical management of Parkinson's diseaseCombating Non-nucleoside Reverse Transcriptase Inhibitor Resistance with a Focus On Etravirine (Intelence) for HIV-1 InfectionHealth 3.0Rosacea: a reviewOmega-3-acid Ethyl Esters (Lovaza) For Severe HypertriglyceridemiaDrug and Device NewsZika in America: The Year in ReviewRivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitorParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisNew Drugs/Drug NewsNew drugs/drug newsNew drugs/drug newsNew Medical DevicesFDA devotes new resources to upgrading generic drug safety: but in some instances, the industry is pushing backNew Medical DevicesNew Medical DevicesNew Medical DevicesNew Medical DevicesSocial media and health care professionals: benefits, risks, and best practicesA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsRole of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular LymphomaMinnesota Pharmacists and Medical Cannabis: A Survey of Knowledge, Concerns, and Interest Prior to Program Launch.Assessment of hospital pharmacy preparedness for mass casualty events.Drawn Curtains, Muted Alarms, and Diverted Attention Lead to Tragedy In the Postanesthesia Care Unit.The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricing.American psychiatric association.'Stage 2' incentive rule for electronic records highlights importance of hospital pharmacy data: republicans say requirements for incentives are set too low.Mismatched prescribing and pharmacy templates for parenteral nutrition lead to data-entry errors.Clinical Trial Transparency Is Up for Grabs: The FDA and Congress Are Expanding Public Access to Data
P1433
Q24561509-C6912DA0-8EB6-4CA5-9D9B-944E74FFB9D6Q24570101-B387A18A-35CD-4B7B-9C17-A9E61C9E29F1Q24603566-2175BEF1-864E-4DC1-AC8A-1ED910794086Q24615412-7277CACB-75A0-4471-96D2-787DE7437953Q24615438-21892C82-1B6E-4ACC-BFF5-D8EC7B5FDA99Q24624519-DD7DBA6F-4B10-4689-A697-ABFA222C2AFAQ24632728-500A07E8-7B35-4CAA-BAA3-0573EF722E5CQ24642024-D67750CF-6A52-4BE6-836F-419C136FBC33Q24644838-01286EC6-5315-40CC-AA9D-5B406177BBE1Q24645310-36928EFA-FA7B-4A62-B382-B5A1E837A0B1Q24645324-F3E8FE79-3582-4862-A796-451AD65A1BBDQ24647827-78258677-3655-47DA-9F32-9E29A91160CFQ24648456-94243AF8-5671-46C2-B3C8-6E2C1334BABFQ24648480-931EBF86-643C-4EE1-B033-B795BB5A2AFBQ24658459-7584599C-6706-46CC-98E4-B3B7B6FB85B3Q24658510-BB00706C-0951-4C40-83A8-03F04CF0F260Q26970820-A342A7C4-F760-45C4-B48E-2D1BAA780651Q28119698-AC63CE4C-9356-45DB-A39E-5E772B0D223EQ28250157-5B9BC124-B92E-44C2-A876-FB419DAB7A0AQ28384572-22844F19-76B9-49BA-9166-CDC42C4832E6Q28472441-42D5E1D8-9324-429B-81C5-52A2B56D06FAQ28479058-36EB1908-2E28-493C-B024-E45CB0465CEEQ28480600-545315CF-1618-49A3-ACC5-71EBA0258980Q28535155-68F2EF59-A65A-4240-A12F-19E58B88533EQ28539010-70368C24-303E-46D5-8059-48A715678EE2Q28547028-DABFBF3D-FA61-4E5A-BB12-1EFA62370678Q28550023-44EF47E3-160F-421E-821C-62A094DF0DB1Q28550421-B346F008-ED5C-46AC-8814-0DD90E70D725Q28551954-AB23335B-7D8E-418E-9816-90E840D216AAQ28655532-0EEAB192-2204-426D-AF90-3EA36871C50BQ28972330-97D2FD2F-8E41-4E39-8322-06B14F6437F2Q28972464-5BE57107-3A88-475E-9DA0-7F26F455485BQ30151563-BD749535-0825-4F25-B1F9-6870D1C7737DQ30204208-6796896F-CFE4-4737-ADED-A9FD52DAFDE3Q30380478-2CAC4496-5C3F-400C-85EA-4EC84602D06BQ30409875-C94F158D-5C28-4247-83E5-4ECD46C3C2B5Q30488788-547B770F-DDFD-4BB6-AA74-D280BBCEBD5FQ30586068-2AA5A021-CF5B-4B8F-9629-07817B02CB26Q30966132-93947ACC-34A2-4D59-BAB6-5CC888E8BE8CQ30981094-C4052331-FD84-4262-8938-D9324FCB9C10
P1433
description
academisch tijdschrift
@nl
journal
@en
name
P & T: journal for formulary management
@en
P & T: journal for formulary management
@nl
type
label
P & T: journal for formulary management
@en
P & T: journal for formulary management
@nl
altLabel
P T
@en
Pharmacy and Therapeutics
@en
prefLabel
P & T: journal for formulary management
@en
P & T: journal for formulary management
@nl
P243
P1055
P1058
P1156
P1159
P1476
P & T: journal for formulary management
@en
P236
P243
P407
P571
1990-01-01T00:00:00Z